Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.

MLA

Climent, Miguel Ángel, et al. “Weekly Cabazitaxel plus Prednisone Is Effective and Less Toxic for ‘Unfit’ Metastatic Castration-Resistant Prostate Cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) Trial.” European Journal of Cancer (Oxford, England : 1990), vol. 87, Dec. 2017, pp. 30–37. EBSCOhost, https://doi.org/10.1016/j.ejca.2017.09.028.

APA

Climent, M. Á., Pérez-Valderrama, B., Mellado, B., Fernández Parra, E. M., Fernández Calvo, O., Ochoa de Olza, M., Muinelo Romay, L., Anido, U., Domenech, M., Hernando Polo, S., Arranz Arija, J. Á., Caballero, C., Juan Fita, M. J., & Castellano, D. (2017). Weekly cabazitaxel plus prednisone is effective and less toxic for “unfit” metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial. European Journal of Cancer (Oxford, England : 1990), 87, 30–37. https://doi.org/10.1016/j.ejca.2017.09.028

Chicago

Climent, Miguel Ángel, Begoña Pérez-Valderrama, Begoña Mellado, Eva María Fernández Parra, Ovidio Fernández Calvo, María Ochoa de Olza, Laura Muinelo Romay, et al. 2017. “Weekly Cabazitaxel plus Prednisone Is Effective and Less Toxic for ‘Unfit’ Metastatic Castration-Resistant Prostate Cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) Trial.” European Journal of Cancer (Oxford, England : 1990) 87 (December): 30–37. doi:10.1016/j.ejca.2017.09.028.